68 results about "Dose level" patented technology

Methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, storing the determined analyte concentration and a time associated with the determined analyte concentration, retrieving two or more stored analyte concentrations, and determining an adjusted dose level based at least in part on a current dose level and data associated with the two or more retrieved analyte concentrations are provided. For example, adjustments to dosage levels of long-acting insulin may be provided to assist in the management of diabetes and related conditions.

A method, code and system for planning the treatment a lesion on or adjacent to the retina of an eye of a patient are disclosed. There is first established at least two beam paths along which x-radiation is to be directed at the retinal lesion. Based on the known spectral and intensity characteristics of the beam, a total treatment time for irradiation along each beam paths is determined. From the coordinates of the optic nerve in the aligned eye position, there is determined the extent and duration of eye movement away from the aligned patient-eye position in a direction that moves the patient's optic nerve toward the irradiation beam that will be allowed during treatment, while still maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

A method, code and system for planning the treatment a lesion on or adjacent to the retina of an eye of a patient are disclosed. There is first established at least two beam paths along which x-radiation is to be directed at the retinal lesion. Based on the known spectral and intensity characteristics of the beam, a total treatment time for irradiation along each beam paths is determined. From the coordinates of the optic nerve in the aligned eye position, there is determined the extent and duration of eye movement away from the aligned patient-eye position in a direction that moves the patient's optic nerve toward the irradiation beam that will be allowed during treatment, while still maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

An accurate method for inversely verifying a therapeutic radiation dose delivered to a patient via an x-ray delivery system without involving any computational iteration was developed. The usage of it includes detecting the transmitted radiation dose image after passage through the patient, imaging the patient during treatment to anatomically record information of the patient, followed by inversely verifying through use of both the detected radiation image and the imaging data, the actual radiation dose delivered to the patient, and comparing the level of the dose delivered to a previously planned dose to determine whether the planned dose was delivered, or whether an overdose or underdose occurred.

Methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, retrieving stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determining a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, where the determined current dose level includes a predetermined type of medication classification are provided. For example, dosage determination of fast or rapid acting insulin, long acting insulin, intermediate acting insulin, or one or more combinations may be provided to assist in the management of diabetes and related conditions.

Disclosed herein is a method for protecting humans in need of such protection from physical damage caused by ionizing radiation comprising administering to said humans on a defined basis prior to and after exposure to such radiation a plurality of antioxidants at a dosage level directly proportional to the radiation level likely to be encountered.

In accordance with the present invention, there are provided methods useful for the treatment of a subject having an infirmity. Invention methods comprise administering to a subject a sub-therapeutic dose level of a pharmacologically active agent (such as the anticancer drug paclitaxel) effective against an infirmity over an administration period sufficient to achieve a therapeutic benefit.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

A method, code and system for planning the treatment a lesion on or adjacent to the retina of an eye of a patient are disclosed. There is first established at least two beam paths along which x-radiation is to be directed at the retinal lesion. Based on the known spectral and intensity characteristics of the beam, a total treatment time for irradiation along each beam paths is determined. From the coordinates of the optic nerve in the aligned eye position, there is determined the extent and duration of eye movement away from the aligned patient-eye position in a direction that moves the patient's optic nerve toward the irradiation beam that will be allowed during treatment, while still maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and / or fever.

Methods and devices for calibrating a radiotherapy system are disclosed. The method includes providing a detection medium that responds to exposure to ionizing radiation, and preparing a calibration dose response pattern by exposing predefined regions of the detection medium to different ionizing radiation dose levels. The method also includes measuring responses of the detection medium in the predefined regions to generate a calibration that relates subsequent responses to ionizing radiation dose. Different dose levels are obtained by differentially shielding portions of the detection medium from the ionizing radiation using, for example, a multi-leaf collimator, a secondary collimator, or an attenuation block. Different dose levels can also be obtained by moving the detection medium between exposures. The disclosed device includes a software routine fixed on a computer-readable medium that is configured to generate a calibration that relates a response of a detection medium to ionizing radiation dose.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

A system displays potential radiation zones in an angiography X-ray laboratory during an angiography procedure, for example, and identifies areas of potentially harmful radiation due to X-ray scatter in an imaging room. An input processor receives data identifying an emitted X-ray dose level applied to an area of a patient anatomy. An image data processor determines level of X-ray radiation dose scatter in different regions of an imaging room indicating regions of potentially harmful radiation, by calculating X-ray scatter dose at different distances from an irradiated patient area as being substantially in proportion to the size of the irradiated area and substantially inversely proportional to the square of the distance from the irradiated area. A visual alert system visually identifies areas of a room of potentially harmful radiation in response to the determination.

Methods and systems are provided for automated tube current modulation (ATCM). In one embodiment, a method for an imaging system comprises: calculating a desired dose level based on a clinical task, a size of a subject to be scanned, and an image quality level; generating a scan protocol based on a relation between the image quality level and at least one characteristic of the imaging system; and performing a scan of the subject at the desired dose level and according to the generated scan protocol. In this way, ATCM can be optimized based on elements that impact image quality such as the clinical task, the physical characteristics of the imaging system, the individual patient, and the reader's preference.

The invention discloses a pharmaceutical composition with the function of treating polycystic ovary syndrome, a preparation method and a quality detection method. The pharmaceutical composition preparation of the invention uses astragalus mongholicus, herba epimedii, rhizoma atractylodis, tuckahoe and red sage root as raw material drugs; various types of preparation can be prepared through a special preparation method. The pharmacodynamics experiment indicates that the pharmaceutical composition can reduce blood sugar and insulin, decrease the content of serum testosterone, and have importantsignificance for treating the polycystic ovary syndrome. A prescription sieving experiment indicates that, when the polycystic ovary syndrome is treated, the optimal dose level range of the pharmaceutical composition is: 50g Astragalus mongholicus, 30g rhizome, 30g tuckahoe, 30g herba epimedii, and 10g the red sage root.

A method for calibrating a radiation detection medium by exposing arbitrary locations of a radiation detection medium to a plurality of known radiation dose levels is described. One particular aspect of the method includes the steps of automatically determining the location of each arbitrary exposed location, measuring the density of each of the arbitrary exposed locations, matching each measurement for the arbitrary exposed locations with the corresponding radiation dose level thereby generating an array of paired data values for radiation dose level and measured density and calculating a calibration based on the array of paired data values.

Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the first drug.

A system displays potential radiation zones in an angiography X-ray laboratory during an angiography procedure, for example, and identifies areas of potentially harmful radiation due to X-ray scatter in an imaging room. An input processor receives data identifying an emitted X-ray dose level applied to an area of a patient anatomy. An image data processor determines level of X-ray radiation dose scatter in different regions of an imaging room indicating regions of potentially harmful radiation, by calculating X-ray scatter dose at different distances from an irradiated patient area as being substantially in proportion to the size of the irradiated area and substantially inversely proportional to the square of the distance from the irradiated area. A visual alert system visually identifies areas of a room of potentially harmful radiation in response to the determination.

A method for treatment of esophageal high grade dysplasia comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having high grade dysplasia tissue to provide a dose level of 3 through 5 mg / m<2> of body surface area, waiting for a time period of 24 through 60 hours to permit preferential absorption of the HPPH into esophageal cancer tissue, and exposing the esophageal cancer tissue to light at a wavelength of about 670 +- 5 nm at an energy of from about 75 to about 200 Joules / cm.

The invention discloses a dedicated breast phantom of CT equipment for breast. The breast phantom comprises an elliptic breast body, a plurality of detector accommodating holes, thermoluminesence detectors, a fixing pin (1) and a fixing pin (2), wherein the elliptic breast body is divided into two elliptic half-balls through an elliptic central plane; the detector accommodating holes are all embedded in either elliptic half-ball; the other elliptic half-ball is used for assisting the formation of breast shape of the breast phantom; the detector accommodating holes are round or small cylinder-shaped; the thermoluminesence detectors are put in the detector accommodating holes and used for data measurement; the four corners of the fixing pin (1) are round; and the air flows out through slits at the four corners to achieve the fixing and buffering functions when the two elliptic half-balls are closed. The dedicated breast phantom can be applied to measure and calibrate the dose of radiation to the breast as well as the dose distribution, is more favorable to control and evaluate the dose level of radiation to the breast, and helps improve breast diagnosis techniques.

Methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, storing the determined analyte concentration and a time associated with the determined analyte concentration, retrieving two or more stored analyte concentrations, and determining an adjusted dose level based at least in part on a current dose level and data associated with the two or more retrieved analyte concentrations are provided. For example, adjustments to dosage levels of long-acting insulin may be provided to assist in the management of diabetes and related conditions.

The invention discloses a device for preparing a radioactive sample. The device comprises a radiation shielding body and a moving carrier, wherein the radiation shielding body comprises a box body; one end of the box body is an open end, and the open end is connected with a side opening door; the top of the box body is provided with an opening group, the opening group comprises at least one opening, and the openings communicate with internal and external spaces of the box body; at least part of the box body and the side opening door is made of a radiation shielding material; and the moving carrier comprises a placing part, the placing part is provided with a clamping groove group, the clamping groove group comprises at least one clamping groove, and the clamping grooves are used for placing an experiment bottle. According to the device, the dosage level of the sample in an experiment process is significantly reduced to a few micro-sieverts, so that experiment operations of dissolutionof the radioactive sample, pH value adjustment and determination, filtration and separation of the sample and the like can be completed outside a glove box, an operator can complete the fine operations more efficiently, experiment time is shortened, time of exposure in a radiation environment is shortened, and the health and safety of experimenters are guaranteed.

A method provides for sterilizing with radiation objects which have a low bioburden and which are sensitive to radiation. A dosage of radiation sufficient to ensure sterilization without damaging the object is determined by determining the bioburden upon one or more samples of the objects, determining an estimate of the dose that results in a preselected probability (e.g., 0.1, 0.01, 0.001, 0.0003162 . . . etc. (i.e., SAL=10−1, 10−2, 10−3, 10−3.5 . . . etc.)) of a surviving microorganism on the objects preferably by testing a quantity of samples of the objects at varying dosage levels of radiation, confirming the estimate by testing a quantity of samples of the objects at the dose that was estimated; and calculating a dosage for the sterility assurance level of 10−6 by adding a factor to the dose that was confirmed to result in said preselected probability of a surviving microorganism on the objects and wherein the factor is proportional to the dose that yields said preselected probability of a surviving microorganism on the objects and inversely proportional to a log of the bioburden.

Disclosed are methods for treating various cancers. Methods encompass the administration of an mTOR inhibitor in combination with a second drug selected from an ImiD, a PDE4 inhibitor, a p38 MAP kinase inhibitor, a xanthine anticytokine, a dual TACE / MMP inhibitor and a proteasome inhibitor.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the mTOR inhibitor.

The invention provides a method for screening an exogenous carbohydrase spectrum of chicken feed. The method comprises the following steps: selecting a target chicken feed; setting the type and the dose level of the added exogenous carbohydrases; in-vitro simulating gastrointestinal digestion of chicken; detecting the in-vitro digestion emergy of the feed; and analyzing the optimal carbohydrase spectrum of the target feed. According to the method, the animal digesting process is simulated in vitro, and the acting effect of the carbohydrases is represented by using the in-vitro emergy, so that the optimal exogenous carbohydrase spectrum of the chicken feed can be quickly obtained.

A method for treatment of esophageal high grade dysplasia comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having high grade dysplasia tissue to provide a dose level of 3 through 5 mg / m2 of body surface area, waiting for a time period of 24 through 60 hours to permit preferential absorption of the HPPH into esophageal cancer tissue, and exposing the esophageal cancer tissue to light at a wavelength of about 670±5 nm at an energy of from about 75 to about 200 Joules / cm.

A sterilized non-discolored eyelid cleansing pad, which has been sterilized by exposure to γ-radiation in a dose level of 2 Mrad.

The invention belongs to the technical field of radiation monitoring, particularly relates to a portable radiation acousto-optic alarm device used for the nuclear power site, and is used for monitoring the radiation situation of a monitoring area in real time and performing acousto-optic alarming. The portable radiation acousto-optic alarm device comprises an alarm lamp (1), a display module (3), a setting module (4), an infrared induction module (5), a voice module (6), a shell (7), a control module (8), a power supply module (9) and a radiation detection module (10). The radiation dose of the monitoring area is detected through the radiation detection module (10) and transmitted to the control module (8), and the dose level is judged by the control module (8) according to the system parameters. The personnel entering the monitoring area are detected through the infrared induction module (5). When someone enters the monitoring area, the infrared induction module (5) triggers signals and transmits the signals to the control module (8), and the alarm lamp (1) and the voice module (6) under the condition of different dose levels are controlled to alarm through the control module (8).